
|Articles|October 4, 2021
UPS Healthcare Expands Global Cold Chain Logistics Network
Advertisement
Marken, the clinical trial logistics operation with UPS Healthcare, has expanded its global network to support increased demand for its clinical drug supply chain services, particularly for cell and gene clinical trials. Plans for the remainder of 2021 and 2022 will support accelerated demand for mRNA therapies, cell and gene therapies, early access and managed access programs. Expansion plans include new locations, expanded cold chain services and packaging solutions.
Marken's ongoing and planned investments include:
- The addition of over 100,000 square feet of GMP-compliant depot operations in Louisville, KY, Great Valley, PA, and Seoul, South Korea.
- A new GMP depot facility in Kiev, Ukraine
- A new GDP depot facility in Osaka, Japan
- New locations in Nairobi, Kenya and Accra, Ghana
- Expansion of its kit assembly facility in Shanghai, China
- New liquid nitrogen (LN2) filling stations within each of its global cell and gene centers of excellence
- Infrastructure expansion at its facilities in Belgium, France, South Africa, India, Taiwan, China, and Singapore
- Packaging and technology enhancements for real-time location tracking and temperature monitoring of cell and gene therapy shipments
This new control center, combined with the existing control center in Durham, NC, US, will support 24/7/365 global monitoring of all complex shipments, including cell and gene shipments.
Advertisement
Related to this article

AI can draft a CSR in minutes, but the report only reflects evidence that has already converged, so faster drafting shifts the bottleneck to upstream reconciliation, database-lock readiness, and human accountability rather than shortening the trial itself.

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, details how NMPA reforms, parallel reviews, and expanded reviewer capacity brought China’s startup timelines in line with the US and Europe, and could shorten them further.

In today’s ACT Brief, we examine why APAC inspection findings mirror those in the US and Europe, how key risk indicators should be read together, and how FDA granted accelerated approval to a subcutaneous antibody therapy for recurrent head and neck cancer.

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how FDA inspection findings at APAC sites compare with those in the US and Europe, and why the common issues, such as informed consent versioning, are not unique to the region.

In today’s ACT Brief, we examine why outdated views of Asia Pacific trial sites persist, how community access gaps reflect both patient costs and site infrastructure, and how VeonGen has aligned with the FDA on a pivotal gene therapy trial design.

Risk-based quality management depends on knowing what to monitor and on interpreting what the signals mean.

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how regulatory reform and inspection data contradict the view that APAC sites are slower or lower quality, and why sponsors need to update their assumptions.

In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The 10 Most Powerful Study KRIs in RBQM and GCP Issues They Can Prevent
2
ACT Brief: APAC Inspection Findings, RBQM Key Risk Indicators, and Head and Neck Cancer Approval
3
What FDA Inspections Reveal About the Quality of APAC Clinical Trial Sites
4
How China Cut Its Phase III Startup Timeline and What Drove the Change
5

